series-a
Stage
About
ErVimmune is a French biotechnology company developing cancer vaccines and T cell-based therapies targeting shared non-conventional tumor antigens derived from human endogenous retroviruses to address unmet medical needs in cold tumors.
Explore ErVimmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.